GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » ROE %

Lexagene Holdings (Lexagene Holdings) ROE % : -350.40% (As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Lexagene Holdings's annualized net income for the quarter that ended in Nov. 2022 was $-6.71 Mil. Lexagene Holdings's average Total Stockholders Equity over the quarter that ended in Nov. 2022 was $1.92 Mil. Therefore, Lexagene Holdings's annualized ROE % for the quarter that ended in Nov. 2022 was -350.40%.

The historical rank and industry rank for Lexagene Holdings's ROE % or its related term are showing as below:

LXXGQ's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.16
* Ranked among companies with meaningful ROE % only.

Lexagene Holdings ROE % Historical Data

The historical data trend for Lexagene Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings ROE % Chart

Lexagene Holdings Annual Data
Trend Mar13 Mar14 Mar15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -182.50 -342.99 -286.22 -134.22 -123.03

Lexagene Holdings Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -215.88 -182.22 -156.47 -238.36 -350.40

Competitive Comparison of Lexagene Holdings's ROE %

For the Medical Devices subindustry, Lexagene Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexagene Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lexagene Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Lexagene Holdings's ROE % falls into.



Lexagene Holdings ROE % Calculation

Lexagene Holdings's annualized ROE % for the fiscal year that ended in Feb. 2022 is calculated as

ROE %=Net Income (A: Feb. 2022 )/( (Total Stockholders Equity (A: Feb. 2021 )+Total Stockholders Equity (A: Feb. 2022 ))/ count )
=-10.62/( (10.884+6.38)/ 2 )
=-10.62/8.632
=-123.03 %

Lexagene Holdings's annualized ROE % for the quarter that ended in Nov. 2022 is calculated as

ROE %=Net Income (Q: Nov. 2022 )/( (Total Stockholders Equity (Q: Aug. 2022 )+Total Stockholders Equity (Q: Nov. 2022 ))/ count )
=-6.712/( (2.558+1.273)/ 2 )
=-6.712/1.9155
=-350.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Nov. 2022) net income data. ROE % is displayed in the 30-year financial page.


Lexagene Holdings  (OTCPK:LXXGQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Nov. 2022 )
=Net Income/Total Stockholders Equity
=-6.712/1.9155
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6.712 / 0.172)*(0.172 / 3.8425)*(3.8425 / 1.9155)
=Net Margin %*Asset Turnover*Equity Multiplier
=-3902.33 %*0.0448*2.006
=ROA %*Equity Multiplier
=-174.82 %*2.006
=-350.40 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Nov. 2022 )
=Net Income/Total Stockholders Equity
=-6.712/1.9155
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-6.712 / -6.712) * (-6.712 / -6.644) * (-6.644 / 0.172) * (0.172 / 3.8425) * (3.8425 / 1.9155)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0102 * -3862.79 % * 0.0448 * 2.006
=-350.40 %

Note: The net income data used here is four times the quarterly (Nov. 2022) net income data. The Revenue data used here is four times the quarterly (Nov. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Lexagene Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexagene Holdings (Lexagene Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915
Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.